Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

Showing products 1–24 of 54. More products

TOPIRAMATE

Form:

24 of 24 products shown

20 general benefit · 2 Limited Use · 2 not a benefit

Other products in the same Health Canada class (N03AX) — coverage varies; not interchangeable

  • Lamotrigine (Lamictal): general benefit
  • Brivaracetam (Brivlera): limited Use 548
  • Cenobamate (Xcopri): limited Use 719
  • Lacosamide (Vimpat): limited Use 430
  • Levetiracetam (PDP-Levetiracetam): limited Use 473, Limited Use 640, 705
  • Perampanel (Fycompa): limited Use 430, 564

14 more in the class list below

Topamax Sprinkle · DIN 02239907 · 15mg · Sprinkle capsule

Limited Use — Reason for Use code 321 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 321 required
Write on scriptLU code 321 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 321
Reason for Use code 321 In children age 16 and under, as adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Topamax Sprinkle · DIN 02239907 Manufacturer: Janssen-Ortho Inc.; listing date 2000-11-30 Health Canada: Marketed since 1999-06-11 · brand TOPAMAX · ATC N03AX11 TOPIRAMATE · form Capsule · route Oral · ingredients TOPIRAMATE 15 MG · company Janssen inc · schedule Prescription
Check this DIN again · Health Canada product record

Topamax Sprinkle: Formulary list price $2.2425/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.2425 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63399 · Verify on the e-Formulary ↗ (DIN 02239907)

Source record
DIN 02239907: Topamax Sprinkle Raw flags: sec12=Y, sec3=Y Item: 281200079; group id 445; item number 1113; lccId 00074; manufacturer id JNO Source form: Sprinkle Cap; strength: 15mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.2425; ministry $2.2425 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02239907 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63399
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02239907
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Topamax Sprinkle · DIN 02239908 · 25mg · Sprinkle capsule

Limited Use — Reason for Use code 321 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 321 required
Write on scriptLU code 321 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 321
Reason for Use code 321 In children age 16 and under, as adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Topamax Sprinkle · DIN 02239908 Manufacturer: Janssen-Ortho Inc.; listing date 2000-11-30 Health Canada: Marketed since 1999-06-11 · brand TOPAMAX · ATC N03AX11 TOPIRAMATE · form Capsule · route Oral · ingredients TOPIRAMATE 25 MG · company Janssen inc · schedule Prescription
Check this DIN again · Health Canada product record

Topamax Sprinkle: Formulary list price $2.3445/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.3445 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63400 · Verify on the e-Formulary ↗ (DIN 02239908)

Source record
DIN 02239908: Topamax Sprinkle Raw flags: sec12=Y, sec3=Y Item: 281200080; group id 445; item number 1114; lccId 00074; manufacturer id JNO Source form: Sprinkle Cap; strength: 25mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.3445; ministry $2.3445 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02239908 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63400
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02239908
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Topiramate · DIN 02279614 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Topiramate · DIN 02279614 Manufacturer: Apotex Inc.; listing date 2006-06-14 Health Canada: Marketed since 2006-04-21 · brand APO-TOPIRAMATE · ATC N03AX11 TOPIRAMATE · form Tablet · route Oral · ingredients TOPIRAMATE 25 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Topiramate: Formulary list price $0.2433/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2433 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76522 · Verify on the e-Formulary ↗ (DIN 02279614)

Source record
DIN 02279614: Apo-Topiramate Raw flags: sec3=Y Item: 281200069; group id 446; item number 1116; lccId None; manufacturer id APX Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.2433; ministry $0.2433 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02279614 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76522
Interchangeable products
AG-Topiramate · DIN 02475936 · $0.2433 Ach-Topiramate · DIN 02395738 · $0.2433 Auro-Topiramate · DIN 02345803 · $0.2433 Jamp Topiramate Tablets · DIN 02345250 · $0.2433 Jamp-Topiramate · DIN 02435608 · $0.2433 Mar-Topiramate · DIN 02432099 · $0.2433 Mint-Topiramate · DIN 02315645 · $0.2433 Mylan-Topiramate · DIN 02263351 · $0.2433 NRA-Topiramate · DIN 02538466 · $0.2433 PMS-Topiramate · DIN 02262991 · $0.2433 Sandoz Topiramate Tablets · DIN 02431807 · $0.2433 Teva-Topiramate · DIN 02248860 · $0.2433 Topamax · DIN 02230893 · $0.2433 Topiramate · DIN 02356856 · $0.2433 Topiramate · DIN 02389460 · $0.2433
Shortage status: resolved shortage (ended 2026-03-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02279614
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Topiramate · DIN 02345803 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Topiramate · DIN 02345803 Manufacturer: Auro Pharma Inc.; listing date 2011-09-15 Health Canada: Marketed since 2020-03-31 · brand AURO-TOPIRAMATE · ATC N03AX11 TOPIRAMATE · form Tablet · route Oral · ingredients TOPIRAMATE 25 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Topiramate: Formulary list price $0.2433/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2433 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83123 · Verify on the e-Formulary ↗ (DIN 02345803)

Source record
DIN 02345803: Auro-Topiramate Raw flags: sec3=Y Item: 281200069; group id 446; item number 1116; lccId None; manufacturer id AUR Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.2433; ministry $0.2433 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02345803 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83123
Interchangeable products
AG-Topiramate · DIN 02475936 · $0.2433 Ach-Topiramate · DIN 02395738 · $0.2433 Apo-Topiramate · DIN 02279614 · $0.2433 Jamp Topiramate Tablets · DIN 02345250 · $0.2433 Jamp-Topiramate · DIN 02435608 · $0.2433 Mar-Topiramate · DIN 02432099 · $0.2433 Mint-Topiramate · DIN 02315645 · $0.2433 Mylan-Topiramate · DIN 02263351 · $0.2433 NRA-Topiramate · DIN 02538466 · $0.2433 PMS-Topiramate · DIN 02262991 · $0.2433 Sandoz Topiramate Tablets · DIN 02431807 · $0.2433 Teva-Topiramate · DIN 02248860 · $0.2433 Topamax · DIN 02230893 · $0.2433 Topiramate · DIN 02356856 · $0.2433 Topiramate · DIN 02389460 · $0.2433
Shortage status: resolved shortage (ended 2024-10-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02345803
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Topiramate Tablets · DIN 02345250 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Topiramate Tablets · DIN 02345250 Manufacturer: Jamp Pharma Corporation; listing date 2023-06-30 Health Canada: Marketed since 2023-03-01 · brand JAMP TOPIRAMATE TABLETS · ATC N03AX11 TOPIRAMATE · form Tablet · route Oral · ingredients TOPIRAMATE 25 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Topiramate Tablets: Formulary list price $0.2433/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2433 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83068 · Verify on the e-Formulary ↗ (DIN 02345250)

Source record
DIN 02345250: Jamp Topiramate Tablets Raw flags: sec3=Y Item: 281200069; group id 446; item number 1116; lccId None; manufacturer id JPC Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.2433; ministry $0.2433 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02345250 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83068
Interchangeable products
AG-Topiramate · DIN 02475936 · $0.2433 Ach-Topiramate · DIN 02395738 · $0.2433 Apo-Topiramate · DIN 02279614 · $0.2433 Auro-Topiramate · DIN 02345803 · $0.2433 Jamp-Topiramate · DIN 02435608 · $0.2433 Mar-Topiramate · DIN 02432099 · $0.2433 Mint-Topiramate · DIN 02315645 · $0.2433 Mylan-Topiramate · DIN 02263351 · $0.2433 NRA-Topiramate · DIN 02538466 · $0.2433 PMS-Topiramate · DIN 02262991 · $0.2433 Sandoz Topiramate Tablets · DIN 02431807 · $0.2433 Teva-Topiramate · DIN 02248860 · $0.2433 Topamax · DIN 02230893 · $0.2433 Topiramate · DIN 02356856 · $0.2433 Topiramate · DIN 02389460 · $0.2433
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02345250
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Topiramate · DIN 02315645 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Topiramate · DIN 02315645 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2009-03-02 Health Canada: Marketed since 2024-06-26 · brand MINT-TOPIRAMATE · ATC N03AX11 TOPIRAMATE · form Tablet · route Oral · ingredients TOPIRAMATE 25 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Topiramate: Formulary list price $0.2433/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2433 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80117 · Verify on the e-Formulary ↗ (DIN 02315645)

Source record
DIN 02315645: Mint-Topiramate Raw flags: sec3=Y Item: 281200069; group id 446; item number 1116; lccId None; manufacturer id MIN Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.2433; ministry $0.2433 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02315645 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80117
Interchangeable products
AG-Topiramate · DIN 02475936 · $0.2433 Ach-Topiramate · DIN 02395738 · $0.2433 Apo-Topiramate · DIN 02279614 · $0.2433 Auro-Topiramate · DIN 02345803 · $0.2433 Jamp Topiramate Tablets · DIN 02345250 · $0.2433 Jamp-Topiramate · DIN 02435608 · $0.2433 Mar-Topiramate · DIN 02432099 · $0.2433 Mylan-Topiramate · DIN 02263351 · $0.2433 NRA-Topiramate · DIN 02538466 · $0.2433 PMS-Topiramate · DIN 02262991 · $0.2433 Sandoz Topiramate Tablets · DIN 02431807 · $0.2433 Teva-Topiramate · DIN 02248860 · $0.2433 Topamax · DIN 02230893 · $0.2433 Topiramate · DIN 02356856 · $0.2433 Topiramate · DIN 02389460 · $0.2433
Shortage status: resolved shortage (ended 2024-03-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02315645
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mylan-Topiramate · DIN 02263351 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mylan-Topiramate · DIN 02263351 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2005-11-08 Health Canada: Marketed since 2009-10-21 · brand MYLAN-TOPIRAMATE · ATC N03AX11 TOPIRAMATE · form Tablet · route Oral · ingredients TOPIRAMATE 25 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Mylan-Topiramate: Formulary list price $0.2433/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2433 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74874 · Verify on the e-Formulary ↗ (DIN 02263351)

Source record
DIN 02263351: Mylan-Topiramate Raw flags: sec3=Y Item: 281200069; group id 446; item number 1116; lccId None; manufacturer id MYL Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.2433; ministry $0.2433 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02263351 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74874
Interchangeable products
AG-Topiramate · DIN 02475936 · $0.2433 Ach-Topiramate · DIN 02395738 · $0.2433 Apo-Topiramate · DIN 02279614 · $0.2433 Auro-Topiramate · DIN 02345803 · $0.2433 Jamp Topiramate Tablets · DIN 02345250 · $0.2433 Jamp-Topiramate · DIN 02435608 · $0.2433 Mar-Topiramate · DIN 02432099 · $0.2433 Mint-Topiramate · DIN 02315645 · $0.2433 NRA-Topiramate · DIN 02538466 · $0.2433 PMS-Topiramate · DIN 02262991 · $0.2433 Sandoz Topiramate Tablets · DIN 02431807 · $0.2433 Teva-Topiramate · DIN 02248860 · $0.2433 Topamax · DIN 02230893 · $0.2433 Topiramate · DIN 02356856 · $0.2433 Topiramate · DIN 02389460 · $0.2433
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02263351
Shortage record checked 2026-09-13T08:10:21.292534+00:00

NRA-Topiramate · DIN 02538466 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
NRA-Topiramate · DIN 02538466 Manufacturer: Nora Pharma; listing date 2024-04-30 Health Canada: Marketed since 2024-01-11 · brand NRA-TOPIRAMATE · ATC N03AX11 TOPIRAMATE · form Tablet · route Oral · ingredients TOPIRAMATE 25 MG · company Nora pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

NRA-Topiramate: Formulary list price $0.2433/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2433 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102718 · Verify on the e-Formulary ↗ (DIN 02538466)

Source record
DIN 02538466: NRA-Topiramate Raw flags: sec3=Y Item: 281200069; group id 446; item number 1116; lccId None; manufacturer id NRA Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.2433; ministry $0.2433 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02538466 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102718
Interchangeable products
AG-Topiramate · DIN 02475936 · $0.2433 Ach-Topiramate · DIN 02395738 · $0.2433 Apo-Topiramate · DIN 02279614 · $0.2433 Auro-Topiramate · DIN 02345803 · $0.2433 Jamp Topiramate Tablets · DIN 02345250 · $0.2433 Jamp-Topiramate · DIN 02435608 · $0.2433 Mar-Topiramate · DIN 02432099 · $0.2433 Mint-Topiramate · DIN 02315645 · $0.2433 Mylan-Topiramate · DIN 02263351 · $0.2433 PMS-Topiramate · DIN 02262991 · $0.2433 Sandoz Topiramate Tablets · DIN 02431807 · $0.2433 Teva-Topiramate · DIN 02248860 · $0.2433 Topamax · DIN 02230893 · $0.2433 Topiramate · DIN 02356856 · $0.2433 Topiramate · DIN 02389460 · $0.2433
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02538466
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Topiramate · DIN 02262991 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Topiramate · DIN 02262991 Manufacturer: Pharmascience Inc.; listing date 2005-11-08 Health Canada: Marketed since 2005-09-14 · brand PMS-TOPIRAMATE · ATC N03AX11 TOPIRAMATE · form Tablet · route Oral · ingredients TOPIRAMATE 25 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Topiramate: Formulary list price $0.2433/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2433 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74840 · Verify on the e-Formulary ↗ (DIN 02262991)

Source record
DIN 02262991: PMS-Topiramate Raw flags: sec3=Y Item: 281200069; group id 446; item number 1116; lccId None; manufacturer id PMS Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.2433; ministry $0.2433 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02262991 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74840
Interchangeable products
AG-Topiramate · DIN 02475936 · $0.2433 Ach-Topiramate · DIN 02395738 · $0.2433 Apo-Topiramate · DIN 02279614 · $0.2433 Auro-Topiramate · DIN 02345803 · $0.2433 Jamp Topiramate Tablets · DIN 02345250 · $0.2433 Jamp-Topiramate · DIN 02435608 · $0.2433 Mar-Topiramate · DIN 02432099 · $0.2433 Mint-Topiramate · DIN 02315645 · $0.2433 Mylan-Topiramate · DIN 02263351 · $0.2433 NRA-Topiramate · DIN 02538466 · $0.2433 Sandoz Topiramate Tablets · DIN 02431807 · $0.2433 Teva-Topiramate · DIN 02248860 · $0.2433 Topamax · DIN 02230893 · $0.2433 Topiramate · DIN 02356856 · $0.2433 Topiramate · DIN 02389460 · $0.2433
Shortage status: resolved shortage (ended 2018-05-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02262991
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Topiramate · DIN 02248860 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Topiramate · DIN 02248860 Manufacturer: Teva Canada Limited; listing date 2005-11-08 Health Canada: Marketed since 2011-05-07 · brand TEVA-TOPIRAMATE · ATC N03AX11 TOPIRAMATE · form Tablet · route Oral · ingredients TOPIRAMATE 25 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Topiramate: Formulary list price $0.2433/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2433 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73232 · Verify on the e-Formulary ↗ (DIN 02248860)

Source record
DIN 02248860: Teva-Topiramate Raw flags: sec3=Y Item: 281200069; group id 446; item number 1116; lccId None; manufacturer id TEV Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.2433; ministry $0.2433 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02248860 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73232
Interchangeable products
AG-Topiramate · DIN 02475936 · $0.2433 Ach-Topiramate · DIN 02395738 · $0.2433 Apo-Topiramate · DIN 02279614 · $0.2433 Auro-Topiramate · DIN 02345803 · $0.2433 Jamp Topiramate Tablets · DIN 02345250 · $0.2433 Jamp-Topiramate · DIN 02435608 · $0.2433 Mar-Topiramate · DIN 02432099 · $0.2433 Mint-Topiramate · DIN 02315645 · $0.2433 Mylan-Topiramate · DIN 02263351 · $0.2433 NRA-Topiramate · DIN 02538466 · $0.2433 PMS-Topiramate · DIN 02262991 · $0.2433 Sandoz Topiramate Tablets · DIN 02431807 · $0.2433 Topamax · DIN 02230893 · $0.2433 Topiramate · DIN 02356856 · $0.2433 Topiramate · DIN 02389460 · $0.2433
Shortage status: resolved shortage (ended 2024-05-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02248860
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Topiramate · DIN 02356856 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Topiramate · DIN 02356856 Manufacturer: Sanis Health Inc.; listing date 2011-08-04 Health Canada: Marketed since 2010-10-06 · brand TOPIRAMATE · ATC N03AX11 TOPIRAMATE · form Tablet · route Oral · ingredients TOPIRAMATE 25 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Topiramate: Formulary list price $0.2433/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2433 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84197 · Verify on the e-Formulary ↗ (DIN 02356856)

Source record
DIN 02356856: Topiramate Raw flags: sec3=Y Item: 281200069; group id 446; item number 1116; lccId None; manufacturer id SAI Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.2433; ministry $0.2433 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02356856 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84197
Interchangeable products
AG-Topiramate · DIN 02475936 · $0.2433 Ach-Topiramate · DIN 02395738 · $0.2433 Apo-Topiramate · DIN 02279614 · $0.2433 Auro-Topiramate · DIN 02345803 · $0.2433 Jamp Topiramate Tablets · DIN 02345250 · $0.2433 Jamp-Topiramate · DIN 02435608 · $0.2433 Mar-Topiramate · DIN 02432099 · $0.2433 Mint-Topiramate · DIN 02315645 · $0.2433 Mylan-Topiramate · DIN 02263351 · $0.2433 NRA-Topiramate · DIN 02538466 · $0.2433 PMS-Topiramate · DIN 02262991 · $0.2433 Sandoz Topiramate Tablets · DIN 02431807 · $0.2433 Teva-Topiramate · DIN 02248860 · $0.2433 Topamax · DIN 02230893 · $0.2433 Topiramate · DIN 02389460 · $0.2433
Shortage status: anticipated shortage (last updated 2026-07-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02356856
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Topiramate · DIN 02389460 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Topiramate · DIN 02389460 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-08-28 Health Canada: Marketed since 2018-07-06 · brand TOPIRAMATE · ATC N03AX11 TOPIRAMATE · form Tablet · route Oral · ingredients TOPIRAMATE 25 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Topiramate: Formulary list price $0.2433/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2433 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87497 · Verify on the e-Formulary ↗ (DIN 02389460)

Source record
DIN 02389460: Topiramate Raw flags: sec3=Y Item: 281200069; group id 446; item number 1116; lccId None; manufacturer id SIV Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.2433; ministry $0.2433 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02389460 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87497
Interchangeable products
AG-Topiramate · DIN 02475936 · $0.2433 Ach-Topiramate · DIN 02395738 · $0.2433 Apo-Topiramate · DIN 02279614 · $0.2433 Auro-Topiramate · DIN 02345803 · $0.2433 Jamp Topiramate Tablets · DIN 02345250 · $0.2433 Jamp-Topiramate · DIN 02435608 · $0.2433 Mar-Topiramate · DIN 02432099 · $0.2433 Mint-Topiramate · DIN 02315645 · $0.2433 Mylan-Topiramate · DIN 02263351 · $0.2433 NRA-Topiramate · DIN 02538466 · $0.2433 PMS-Topiramate · DIN 02262991 · $0.2433 Sandoz Topiramate Tablets · DIN 02431807 · $0.2433 Teva-Topiramate · DIN 02248860 · $0.2433 Topamax · DIN 02230893 · $0.2433 Topiramate · DIN 02356856 · $0.2433
Shortage status: resolved shortage (ended 2017-10-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02389460
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Topiramate · DIN 02279630 · 100mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Topiramate · DIN 02279630 Manufacturer: Apotex Inc.; listing date 2006-06-14 Health Canada: Marketed since 2006-04-21 · brand APO-TOPIRAMATE · ATC N03AX11 TOPIRAMATE · form Tablet · route Oral · ingredients TOPIRAMATE 100 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Topiramate: Formulary list price $0.4583/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4583 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76524 · Verify on the e-Formulary ↗ (DIN 02279630)

Source record
DIN 02279630: Apo-Topiramate Raw flags: sec3=Y Item: 281200070; group id 446; item number 1117; lccId None; manufacturer id APX Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $0.4583; ministry $0.4583 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02279630 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76524
Interchangeable products
AG-Topiramate · DIN 02475944 · $0.4583 Ach-Topiramate · DIN 02395746 · $0.4583 Auro-Topiramate · DIN 02345838 · $0.4583 Jamp Topiramate Tablets · DIN 02345269 · $0.4583 Jamp-Topiramate · DIN 02435616 · $0.4583 Mar-Topiramate · DIN 02432102 · $0.4583 Mint-Topiramate · DIN 02315653 · $0.4583 Mylan-Topiramate · DIN 02263378 · $0.4583 NRA-Topiramate · DIN 02538458 · $0.4583 PMS-Topiramate · DIN 02263009 · $0.4583 Ran-Topiramate · DIN 02396084 · $0.4583 Sandoz Topiramate Tablets · DIN 02431815 · $0.4583 Teva-Topiramate · DIN 02248861 · $0.4583 Topamax · DIN 02230894 · $0.4583 Topiramate · DIN 02356864 · $0.4583 Topiramate · DIN 02389487 · $0.4583
Shortage status: resolved shortage (ended 2025-12-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02279630
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Topiramate · DIN 02345838 · 100mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Topiramate · DIN 02345838 Manufacturer: Auro Pharma Inc.; listing date 2011-09-15 Health Canada: Marketed since 2020-03-31 · brand AURO-TOPIRAMATE · ATC N03AX11 TOPIRAMATE · form Tablet · route Oral · ingredients TOPIRAMATE 100 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Topiramate: Formulary list price $0.4583/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4583 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83125 · Verify on the e-Formulary ↗ (DIN 02345838)

Source record
DIN 02345838: Auro-Topiramate Raw flags: sec3=Y Item: 281200070; group id 446; item number 1117; lccId None; manufacturer id AUR Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $0.4583; ministry $0.4583 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02345838 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83125
Interchangeable products
AG-Topiramate · DIN 02475944 · $0.4583 Ach-Topiramate · DIN 02395746 · $0.4583 Apo-Topiramate · DIN 02279630 · $0.4583 Jamp Topiramate Tablets · DIN 02345269 · $0.4583 Jamp-Topiramate · DIN 02435616 · $0.4583 Mar-Topiramate · DIN 02432102 · $0.4583 Mint-Topiramate · DIN 02315653 · $0.4583 Mylan-Topiramate · DIN 02263378 · $0.4583 NRA-Topiramate · DIN 02538458 · $0.4583 PMS-Topiramate · DIN 02263009 · $0.4583 Ran-Topiramate · DIN 02396084 · $0.4583 Sandoz Topiramate Tablets · DIN 02431815 · $0.4583 Teva-Topiramate · DIN 02248861 · $0.4583 Topamax · DIN 02230894 · $0.4583 Topiramate · DIN 02356864 · $0.4583 Topiramate · DIN 02389487 · $0.4583
Shortage status: resolved shortage (ended 2025-02-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02345838
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Topiramate Tablets · DIN 02345269 · 100mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Topiramate Tablets · DIN 02345269 Manufacturer: Jamp Pharma Corporation; listing date 2024-04-30 Health Canada: Marketed since 2024-02-28 · brand JAMP TOPIRAMATE TABLETS · ATC N03AX11 TOPIRAMATE · form Tablet · route Oral · ingredients TOPIRAMATE 100 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Topiramate Tablets: Formulary list price $0.4583/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4583 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83069 · Verify on the e-Formulary ↗ (DIN 02345269)

Source record
DIN 02345269: Jamp Topiramate Tablets Raw flags: sec3=Y Item: 281200070; group id 446; item number 1117; lccId None; manufacturer id JPC Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $0.4583; ministry $0.4583 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02345269 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83069
Interchangeable products
AG-Topiramate · DIN 02475944 · $0.4583 Ach-Topiramate · DIN 02395746 · $0.4583 Apo-Topiramate · DIN 02279630 · $0.4583 Auro-Topiramate · DIN 02345838 · $0.4583 Jamp-Topiramate · DIN 02435616 · $0.4583 Mar-Topiramate · DIN 02432102 · $0.4583 Mint-Topiramate · DIN 02315653 · $0.4583 Mylan-Topiramate · DIN 02263378 · $0.4583 NRA-Topiramate · DIN 02538458 · $0.4583 PMS-Topiramate · DIN 02263009 · $0.4583 Ran-Topiramate · DIN 02396084 · $0.4583 Sandoz Topiramate Tablets · DIN 02431815 · $0.4583 Teva-Topiramate · DIN 02248861 · $0.4583 Topamax · DIN 02230894 · $0.4583 Topiramate · DIN 02356864 · $0.4583 Topiramate · DIN 02389487 · $0.4583
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02345269
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Topiramate · DIN 02315653 · 100mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Topiramate · DIN 02315653 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2009-03-02 Health Canada: Marketed since 2024-06-26 · brand MINT-TOPIRAMATE · ATC N03AX11 TOPIRAMATE · form Tablet · route Oral · ingredients TOPIRAMATE 100 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Topiramate: Formulary list price $0.4583/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4583 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80118 · Verify on the e-Formulary ↗ (DIN 02315653)

Source record
DIN 02315653: Mint-Topiramate Raw flags: sec3=Y Item: 281200070; group id 446; item number 1117; lccId None; manufacturer id MIN Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $0.4583; ministry $0.4583 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02315653 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80118
Interchangeable products
AG-Topiramate · DIN 02475944 · $0.4583 Ach-Topiramate · DIN 02395746 · $0.4583 Apo-Topiramate · DIN 02279630 · $0.4583 Auro-Topiramate · DIN 02345838 · $0.4583 Jamp Topiramate Tablets · DIN 02345269 · $0.4583 Jamp-Topiramate · DIN 02435616 · $0.4583 Mar-Topiramate · DIN 02432102 · $0.4583 Mylan-Topiramate · DIN 02263378 · $0.4583 NRA-Topiramate · DIN 02538458 · $0.4583 PMS-Topiramate · DIN 02263009 · $0.4583 Ran-Topiramate · DIN 02396084 · $0.4583 Sandoz Topiramate Tablets · DIN 02431815 · $0.4583 Teva-Topiramate · DIN 02248861 · $0.4583 Topamax · DIN 02230894 · $0.4583 Topiramate · DIN 02356864 · $0.4583 Topiramate · DIN 02389487 · $0.4583
Shortage status: resolved shortage (ended 2024-10-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02315653
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mylan-Topiramate · DIN 02263378 · 100mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mylan-Topiramate · DIN 02263378 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2005-11-08 Health Canada: Marketed since 2010-02-04 · brand MYLAN-TOPIRAMATE · ATC N03AX11 TOPIRAMATE · form Tablet · route Oral · ingredients TOPIRAMATE 100 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Mylan-Topiramate: Formulary list price $0.4583/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4583 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74875 · Verify on the e-Formulary ↗ (DIN 02263378)

Source record
DIN 02263378: Mylan-Topiramate Raw flags: sec3=Y Item: 281200070; group id 446; item number 1117; lccId None; manufacturer id MYL Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $0.4583; ministry $0.4583 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02263378 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74875
Interchangeable products
AG-Topiramate · DIN 02475944 · $0.4583 Ach-Topiramate · DIN 02395746 · $0.4583 Apo-Topiramate · DIN 02279630 · $0.4583 Auro-Topiramate · DIN 02345838 · $0.4583 Jamp Topiramate Tablets · DIN 02345269 · $0.4583 Jamp-Topiramate · DIN 02435616 · $0.4583 Mar-Topiramate · DIN 02432102 · $0.4583 Mint-Topiramate · DIN 02315653 · $0.4583 NRA-Topiramate · DIN 02538458 · $0.4583 PMS-Topiramate · DIN 02263009 · $0.4583 Ran-Topiramate · DIN 02396084 · $0.4583 Sandoz Topiramate Tablets · DIN 02431815 · $0.4583 Teva-Topiramate · DIN 02248861 · $0.4583 Topamax · DIN 02230894 · $0.4583 Topiramate · DIN 02356864 · $0.4583 Topiramate · DIN 02389487 · $0.4583
Shortage status: resolved shortage (ended 2024-05-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02263378
Shortage record checked 2026-09-13T08:10:21.292534+00:00

NRA-Topiramate · DIN 02538458 · 100mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
NRA-Topiramate · DIN 02538458 Manufacturer: Nora Pharma; listing date 2024-04-30 Health Canada: Marketed since 2024-01-11 · brand NRA-TOPIRAMATE · ATC N03AX11 TOPIRAMATE · form Tablet · route Oral · ingredients TOPIRAMATE 100 MG · company Nora pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

NRA-Topiramate: Formulary list price $0.4583/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4583 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102717 · Verify on the e-Formulary ↗ (DIN 02538458)

Source record
DIN 02538458: NRA-Topiramate Raw flags: sec3=Y Item: 281200070; group id 446; item number 1117; lccId None; manufacturer id NRA Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $0.4583; ministry $0.4583 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02538458 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102717
Interchangeable products
AG-Topiramate · DIN 02475944 · $0.4583 Ach-Topiramate · DIN 02395746 · $0.4583 Apo-Topiramate · DIN 02279630 · $0.4583 Auro-Topiramate · DIN 02345838 · $0.4583 Jamp Topiramate Tablets · DIN 02345269 · $0.4583 Jamp-Topiramate · DIN 02435616 · $0.4583 Mar-Topiramate · DIN 02432102 · $0.4583 Mint-Topiramate · DIN 02315653 · $0.4583 Mylan-Topiramate · DIN 02263378 · $0.4583 PMS-Topiramate · DIN 02263009 · $0.4583 Ran-Topiramate · DIN 02396084 · $0.4583 Sandoz Topiramate Tablets · DIN 02431815 · $0.4583 Teva-Topiramate · DIN 02248861 · $0.4583 Topamax · DIN 02230894 · $0.4583 Topiramate · DIN 02356864 · $0.4583 Topiramate · DIN 02389487 · $0.4583
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02538458
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Topiramate · DIN 02263009 · 100mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Topiramate · DIN 02263009 Manufacturer: Pharmascience Inc.; listing date 2005-11-08 Health Canada: Marketed since 2005-09-14 · brand PMS-TOPIRAMATE · ATC N03AX11 TOPIRAMATE · form Tablet · route Oral · ingredients TOPIRAMATE 100 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Topiramate: Formulary list price $0.4583/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4583 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74841 · Verify on the e-Formulary ↗ (DIN 02263009)

Source record
DIN 02263009: PMS-Topiramate Raw flags: sec3=Y Item: 281200070; group id 446; item number 1117; lccId None; manufacturer id PMS Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $0.4583; ministry $0.4583 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02263009 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74841
Interchangeable products
AG-Topiramate · DIN 02475944 · $0.4583 Ach-Topiramate · DIN 02395746 · $0.4583 Apo-Topiramate · DIN 02279630 · $0.4583 Auro-Topiramate · DIN 02345838 · $0.4583 Jamp Topiramate Tablets · DIN 02345269 · $0.4583 Jamp-Topiramate · DIN 02435616 · $0.4583 Mar-Topiramate · DIN 02432102 · $0.4583 Mint-Topiramate · DIN 02315653 · $0.4583 Mylan-Topiramate · DIN 02263378 · $0.4583 NRA-Topiramate · DIN 02538458 · $0.4583 Ran-Topiramate · DIN 02396084 · $0.4583 Sandoz Topiramate Tablets · DIN 02431815 · $0.4583 Teva-Topiramate · DIN 02248861 · $0.4583 Topamax · DIN 02230894 · $0.4583 Topiramate · DIN 02356864 · $0.4583 Topiramate · DIN 02389487 · $0.4583
Shortage status: resolved shortage (ended 2026-02-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02263009
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Topiramate · DIN 02248861 · 100mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Topiramate · DIN 02248861 Manufacturer: Teva Canada Limited; listing date 2005-11-08 Health Canada: Marketed since 2011-05-07 · brand TEVA-TOPIRAMATE · ATC N03AX11 TOPIRAMATE · form Tablet · route Oral · ingredients TOPIRAMATE 100 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Topiramate: Formulary list price $0.4583/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4583 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73233 · Verify on the e-Formulary ↗ (DIN 02248861)

Source record
DIN 02248861: Teva-Topiramate Raw flags: sec3=Y Item: 281200070; group id 446; item number 1117; lccId None; manufacturer id TEV Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $0.4583; ministry $0.4583 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02248861 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73233
Interchangeable products
AG-Topiramate · DIN 02475944 · $0.4583 Ach-Topiramate · DIN 02395746 · $0.4583 Apo-Topiramate · DIN 02279630 · $0.4583 Auro-Topiramate · DIN 02345838 · $0.4583 Jamp Topiramate Tablets · DIN 02345269 · $0.4583 Jamp-Topiramate · DIN 02435616 · $0.4583 Mar-Topiramate · DIN 02432102 · $0.4583 Mint-Topiramate · DIN 02315653 · $0.4583 Mylan-Topiramate · DIN 02263378 · $0.4583 NRA-Topiramate · DIN 02538458 · $0.4583 PMS-Topiramate · DIN 02263009 · $0.4583 Ran-Topiramate · DIN 02396084 · $0.4583 Sandoz Topiramate Tablets · DIN 02431815 · $0.4583 Topamax · DIN 02230894 · $0.4583 Topiramate · DIN 02356864 · $0.4583 Topiramate · DIN 02389487 · $0.4583
Shortage status: resolved shortage (ended 2025-08-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02248861
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Topiramate · DIN 02356864 · 100mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Topiramate · DIN 02356864 Manufacturer: Sanis Health Inc.; listing date 2011-08-04 Health Canada: Marketed since 2010-10-06 · brand TOPIRAMATE · ATC N03AX11 TOPIRAMATE · form Tablet · route Oral · ingredients TOPIRAMATE 100 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Topiramate: Formulary list price $0.4583/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4583 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84198 · Verify on the e-Formulary ↗ (DIN 02356864)

Source record
DIN 02356864: Topiramate Raw flags: sec3=Y Item: 281200070; group id 446; item number 1117; lccId None; manufacturer id SAI Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $0.4583; ministry $0.4583 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02356864 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84198
Interchangeable products
AG-Topiramate · DIN 02475944 · $0.4583 Ach-Topiramate · DIN 02395746 · $0.4583 Apo-Topiramate · DIN 02279630 · $0.4583 Auro-Topiramate · DIN 02345838 · $0.4583 Jamp Topiramate Tablets · DIN 02345269 · $0.4583 Jamp-Topiramate · DIN 02435616 · $0.4583 Mar-Topiramate · DIN 02432102 · $0.4583 Mint-Topiramate · DIN 02315653 · $0.4583 Mylan-Topiramate · DIN 02263378 · $0.4583 NRA-Topiramate · DIN 02538458 · $0.4583 PMS-Topiramate · DIN 02263009 · $0.4583 Ran-Topiramate · DIN 02396084 · $0.4583 Sandoz Topiramate Tablets · DIN 02431815 · $0.4583 Teva-Topiramate · DIN 02248861 · $0.4583 Topamax · DIN 02230894 · $0.4583 Topiramate · DIN 02389487 · $0.4583
Shortage status: anticipated shortage (last updated 2026-07-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02356864
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Topiramate · DIN 02389487 · 100mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Topiramate · DIN 02389487 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-08-28 Health Canada: Marketed since 2018-05-04 · brand TOPIRAMATE · ATC N03AX11 TOPIRAMATE · form Tablet · route Oral · ingredients TOPIRAMATE 100 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Topiramate: Formulary list price $0.4583/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4583 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87499 · Verify on the e-Formulary ↗ (DIN 02389487)

Source record
DIN 02389487: Topiramate Raw flags: sec3=Y Item: 281200070; group id 446; item number 1117; lccId None; manufacturer id SIV Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $0.4583; ministry $0.4583 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02389487 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87499
Interchangeable products
AG-Topiramate · DIN 02475944 · $0.4583 Ach-Topiramate · DIN 02395746 · $0.4583 Apo-Topiramate · DIN 02279630 · $0.4583 Auro-Topiramate · DIN 02345838 · $0.4583 Jamp Topiramate Tablets · DIN 02345269 · $0.4583 Jamp-Topiramate · DIN 02435616 · $0.4583 Mar-Topiramate · DIN 02432102 · $0.4583 Mint-Topiramate · DIN 02315653 · $0.4583 Mylan-Topiramate · DIN 02263378 · $0.4583 NRA-Topiramate · DIN 02538458 · $0.4583 PMS-Topiramate · DIN 02263009 · $0.4583 Ran-Topiramate · DIN 02396084 · $0.4583 Sandoz Topiramate Tablets · DIN 02431815 · $0.4583 Teva-Topiramate · DIN 02248861 · $0.4583 Topamax · DIN 02230894 · $0.4583 Topiramate · DIN 02356864 · $0.4583
Shortage status: resolved shortage (ended 2018-05-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02389487
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp-Topiramate Tablets · DIN 02544377 · 50mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp-Topiramate Tablets · DIN 02544377 Manufacturer: Jamp Pharma Corporation; listing date 2024-11-29 Health Canada: Marketed since 2024-08-28 · brand JAMP TOPIRAMATE TABLETS · ATC N03AX11 TOPIRAMATE · form Tablet · route Oral · ingredients TOPIRAMATE 50 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103293 · Verify on the e-Formulary ↗ (DIN 02544377)

Source record
DIN 02544377: Jamp-Topiramate Tablets Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281200188; group id 446; item number 1115; lccId None; manufacturer id JPC Source form: Tab; strength: 50mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.2434; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02544377 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103293
Interchangeable products
PMS-Topiramate · DIN 02312085 · not recorded Topamax · DIN 02231385 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02544377
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Topiramate · DIN 02312085 · 50mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Topiramate · DIN 02312085 Manufacturer: Pharmascience Inc.; listing date 2025-02-28 Health Canada: Marketed since 2008-06-17 · brand PMS-TOPIRAMATE · ATC N03AX11 TOPIRAMATE · form Tablet · route Oral · ingredients TOPIRAMATE 50 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79760 · Verify on the e-Formulary ↗ (DIN 02312085)

Source record
DIN 02312085: PMS-Topiramate Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281200188; group id 446; item number 1115; lccId None; manufacturer id PMS Source form: Tab; strength: 50mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.2434; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02312085 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79760
Interchangeable products
Jamp-Topiramate Tablets · DIN 02544377 · not recorded Topamax · DIN 02231385 · not recorded
Shortage status: active shortage (reported 2026-08-21, estimated to end 2026-10-06, last updated 2026-08-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02312085
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:12 Anticonvulsants) and how they are covered

Matched class: 28:12 Anticonvulsants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CLONAZEPAM, DIVALPROEX SODIUM, ETHOSUXIMIDE, LAMOTRIGINE, VALPROATE SODIUM Some products covered without a code (check the product listing): CARBAMAZEPINE, GABAPENTIN, PHENYTOIN (DIPHENYLHYDANTOIN), PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM, PREGABALIN, PRIMIDONE, VALPROIC ACID 28:12 Anticonvulsants

LAMOTRIGINE

· 28 products · General benefit · strengths: 25mg, 100mg, 150mg · Tab

BRIVARACETAM

· 12 products · Limited Use, codes 548 · strengths: 10mg, 25mg, 50mg, 75mg, 100mg · Tab

CENOBAMATE

· 9 products · Limited Use, codes 719 · strengths: 12.5mg, 25mg, 50mg, 100mg, 150mg, 200mg, 12.5mg & 25mg, 50mg & 100mg, 150mg & 200mg · Tab, Tab - (Starter Kit)

LACOSAMIDE

· 44 products · Limited Use, codes 430 · strengths: 50mg, 100mg, 150mg, 200mg · Tab

LEVETIRACETAM

· 49 products · Limited Use, codes 640, 705 (3), Limited Use, codes 473 (46) · strengths: 100mg/mL, 250mg, 500mg, 750mg, 1000mg · Oral Sol, Tab

PERAMPANEL

· 12 products · Limited Use, codes 430, 564 · strengths: 2mg, 4mg, 6mg, 8mg, 10mg, 12mg · Tab

CARBAMAZEPINE

· 15 products · Listed, not a benefit (3), General benefit (6), Temporary benefit (2), Limited Use, codes 67 (4) · strengths: 100mg, 200mg, 400mg, 100mg/5mL · Chew Tab, ER Tab, LA Tab, Oral Susp, Tab

CLONAZEPAM

· 9 products · General benefit · strengths: 0.5mg, 2mg · Tab

DIVALPROEX SODIUM

· 9 products · General benefit · strengths: 125mg, 250mg, 500mg · Ent Tab

ETHOSUXIMIDE

· 4 products · General benefit · strengths: 250mg, 50mg/mL · Cap, O/L

PHENYTOIN (DIPHENYLHYDANTOIN)

· 4 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2), General benefit (2) · strengths: 6mg/mL, 25mg/mL, 50mg · O/L, Tab

PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM

· 4 products · General benefit (3), Limited Use, codes 481, 657 (1) · strengths: 30mg, 100mg, 50mg/mL · Cap, Inj Sol (Preservative Free) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:12 and 11 more
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications Epilepsy TOPAMAX® (topiramate) is indicated: • as monotherapy for the management of patients (adults and children six years and older) with newly diagnosed epilepsy. • as adjunctive therapy for the management of patients (adults and children two years and older) with epilepsy who are not satisfactorily controlled with conventional therapy. Migraine Prophylaxis Topamax is indicated in adults for the prophylaxis of migraine headache. Prophylactic treatment of migraine may be considered in situations such as: adults experiencing four or more migraine attacks per month who fail to respond adequately to acute abortive therapy; recurring attacks that significantly interfere with the patient’s daily routine; a pattern of increasing migraine attacks over time, with the risk of developing rebound headache from acute abortive therapies; or failure of, or contraindication to, or troublesome side effects from acute abortive medications. Continuing therapy should be reviewed every six months. Topamax should not be used in the acute treatment of migraine attacks. Safety and efficacy of topiramate in the management or prevention of cluster headache… https://pdf.hres.ca/dpd_pm/00081153.PDF PM date: 2025-07-23 Source product: TOPAMAX; DIN 02239907; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

PMS-Topiramate · DIN 02312085 Shortage status: active shortage (reported 2026-08-21, estimated to end 2026-10-06, last updated 2026-08-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02312085

Check this DIN again

Other review policies

For Jamp-Topiramate Tablets, PMS-Topiramate: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026